CVS Up on Medicare Advantage Strength: Is It a Buy Before Q2 Earnings?

CVS Health (CVS) stock has rallied nearly 50% year-to-date, fueled by robust Q1 2025 results, including a 7% revenue increase and adjusted EPS of $2.25, and a raised 2025 EPS guidance to $6.00-$6.20. A key catalyst is the Senate's decision to remove proposed PBM limits and Medicare Advantage cuts from the tax bill, significantly reducing regulatory risk for its Caremark and Aetna segments. This, coupled with broad-based segment growth and an attractive valuation (forward P/E 9.83x), positions CVS for continued investor confidence and potential growth ahead of its Q2 earnings.

Analysis

CVS Health is exhibiting significant positive momentum, driven by both fundamental strength and a favorable shift in the regulatory landscape. The primary catalyst is the Senate's removal of proposed limits on Pharmacy Benefit Managers (PBMs) and cuts to Medicare Advantage, which materially de-risks the outlook for its core Caremark and Aetna business units. This regulatory relief is compounded by strong first-quarter 2025 financial results, where the company reported a 7% year-over-year revenue increase and a substantial rise in adjusted EPS to $2.25. The performance was broad-based, with the Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments growing 8%, 7.9%, and 11.1% respectively. Management's confidence is underscored by an upward revision of its full-year 2025 adjusted EPS guidance to $6.00-$6.20. This operational strength has fueled a nearly 50% year-to-date stock price increase, starkly outperforming peers like Cigna (+10.9%) and UnitedHealth (-39.2%). From a valuation perspective, CVS trades at a forward P/E of 9.83x, representing a significant discount to the S&P 500 and competitor UnitedHealth, suggesting a potentially attractive entry point given its demonstrated growth and improved outlook.

Key Decisions for Investors

• Given the combination of easing regulatory overhang, strong Q1 execution, and upgraded full-year guidance, investors may view the current valuation as an attractive opportunity for exposure to a stable, growth-oriented healthcare provider.
• The significant year-to-date outperformance of CVS against UnitedHealth suggests a potential relative value opportunity; investors could consider overweighting CVS within a healthcare portfolio, capitalizing on its current momentum versus struggling peers.
• The upcoming second-quarter earnings release on July 30, 2025, is a critical catalyst, and investors should closely monitor these results to confirm the continuation of broad-based segment growth and operational efficiency trends reported in Q1.
• With a forward P/E of 9.83x, institutional investors should assess if the premium to Cigna's 9.63x P/E is justified by CVS's scale, integrated care delivery model, and strategic focus on value-based care as highlighted in the report.